Ibrutinib is an orally administered covalent Bruton’s tyrosine kinase (BTK) inhibitor that has been approved for a variety of B-cell malignancies and graft-versus-host disease by US Food and Drug Administration (FOOD&;Drug, 2017). Here, BTK is linked to graft versus host disease.